Omidria

Systemic overdosage of phenylephrine may cause a rise in blood pressure. It may also cause headache, anxiety, nausea, vomiting, and ventricular arrhythmias.

Omidria is not approved for use in children.

Omidria is contraindicated in patients with a known hypersensitivity to any of its ingredients. It should be used with caution in individuals who have previously exhibited sensitivities to NSAIDs.

Pregnancy Category C. It is not known whether Omidria can cause fetal harm when administered to a pregnant woman. It should only be used if clearly needed.

Caution should be exercised when Omidria is administered to women who are breastfeeding.

The most common side effects reported include eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Omidria is diluted prior to use with an ophthalmic irrigating solution. The solution is then used as needed for the surgical procedure.

Active ingredients: phenylephrine hydrochloride and ketorolac tromethamine

Inactive ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injection; may include sodium hydroxide and/or hydrochloric acid for pH adjustment.

Omidria is manufactured by Seattle-based biopharmaceutical company Omeros Corporation.